The approval of a new medication represents new options for patients. But the new option isn't always the best option. When it comes to treating HER-2 positive breast cancer, the standard medication still appears to beat the newer option.

For the first time in its history, the US Food and Drug Administration has approved a medication for the pre-surgical (neoadjuvant) treatment of early-stage (I, II) breast cancer.

HER2-positive breast cancer is one of the most aggressive forms of the disease. A new treatment option may soon be available to help battle this vicious cancer.